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ABSTRACT
Introduction Studies addressing the development and/
or validation of diagnostic and prognostic prediction 
models are abundant in most clinical domains. Systematic 
reviews have shown that the methodological and reporting 
quality of prediction model studies is suboptimal. Due to 
the increasing availability of larger, routinely collected 
and complex medical data, and the rising application 
of Artificial Intelligence (AI) or machine learning (ML) 
techniques, the number of prediction model studies is 
expected to increase even further. Prediction models 
developed using AI or ML techniques are often labelled as 
a ‘black box’ and little is known about their methodological 
and reporting quality. Therefore, this comprehensive 
systematic review aims to evaluate the reporting quality, 
the methodological conduct, and the risk of bias of 
prediction model studies that applied ML techniques for 
model development and/or validation.
Methods and analysis A search will be performed in 
PubMed to identify studies developing and/or validating 
prediction models using any ML methodology and across 
all medical fields. Studies will be included if they were 
published between January 2018 and December 2019, 
predict patient- related outcomes, use any study design or 
data source, and available in English. Screening of search 
results and data extraction from included articles will be 
performed by two independent reviewers. The primary 
outcomes of this systematic review are: (1) the adherence 
of ML- based prediction model studies to the Transparent 
Reporting of a multivariable prediction model for Individual 
Prognosis Or Diagnosis (TRIPOD), and (2) the risk of bias in 
such studies as assessed using the Prediction model Risk 
Of Bias ASsessment Tool (PROBAST). A narrative synthesis 
will be conducted for all included studies. Findings will be 
stratified by study type, medical field and prevalent ML 
methods, and will inform necessary extensions or updates 
of TRIPOD and PROBAST to better address prediction 
model studies that used AI or ML techniques.
Ethics and dissemination Ethical approval is not 
required for this study because only available published 
data will be analysed. Findings will be disseminated 
through peer- reviewed publications and scientific 
conferences.
Systematic review registration PROSPERO, 
CRD42019161764.
INTRODUCTION
Clinical prediction models aim to estimate 
the individualised probability that a particular 
outcome, for example, condition or disease, 
is present (diagnostic models) or whether 
a specific outcome will occur in the future 
(prognostic models).1–4 Studies addressing 
the development, validation and updating of 
prediction models are abundant in most clin-
ical domains. For example, in cardiovascular 
disease, more than 350 prediction models 
have been developed and only a few have 
been validated.5 Moreover, systematic reviews 
have shown that, within different medical 
domains, the methodological and reporting 
quality of prediction model studies is subop-
timal.6–10 Due to the increasing availability 
Strengths and limitations of this study
 ► This protocol increases transparency to the meth-
ods and definitions used in our review and that are 
applied to develop prediction model studies using 
artificial intelligence or machine learning.
 ► The systematic review will provide an overview and 
critical appraisal of the methodological and report-
ing quality, and risk of bias of prediction model stud-
ies using machine learning.
 ► The findings of this review will provide the needed 
evidence for the development of tailored method-
ological and reporting guidelines for prediction mod-
el studies based on machine learning techniques.
 ► We will build a sensitivity search strategy by using 
terms related to machine learning techniques, as 
well as conventional prediction techniques.
 ► Language restriction to English might exclude addi-
tional studies published in other languages.
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of larger, routinely collected and complex medical data, 
and the rising application of Artificial Intelligence (AI) 
or machine learning (ML) techniques for clinical predic-
tion, the number of prediction model studies is expected 
to increase even further.
ML can be described as techniques that directly and 
automatically learn from data without being explicitly 
programmed for that task, and often without any prior 
assumption.11–13 Thus, ML relies on patterns and infer-
ences from the data itself. A perceived advantage of 
ML over conventional statistical techniques is its ability 
to analyse ‘big’, non- linear and high- dimensional data, 
and thus its ability to model complex associations and 
scenarios. Due to the novelty, diversity, flexibility and 
complexity of ML techniques, ML- based prediction 
model studies are often considered as uninterpretable 
for many users. Inadequate reporting of, for example, 
data sources, study design, modelling processes, number 
of predictors and other data assumptions, makes predic-
tion models developed with ML techniques published in 
medical journals difficult to interpret and to be validated 
by other researchers, creating barriers to their use in daily 
clinical practice.
Complete reporting is essential to judge the validity of 
any prediction model as it facilitates: study replication, 
independent validation of the prediction model, risk 
of bias assessments, interpretation of the results, meta- 
analysis of prediction models, and the judgement of 
the value and applicability of such model in real clinical 
settings for individualised predictions.14 While complete 
reporting reveals the strengths and limitations of a predic-
tion model, it also enhances the use and implementation 
of prediction model in clinical practice. The ‘Transparent 
Reporting of a multivariable prediction model for Indi-
vidual Prognosis Or Diagnosis (TRIPOD)’ statement has 
been available since 2015, providing a checklist of 22 
items considered essential for informative reporting of 
diagnostic or prognostic prediction model studies.15 16 
Similarly, the Prediction model Risk Of Bias ASsessment 
Tool (PROBAST) was published in 2019 to guide the crit-
ical appraisal of prediction model studies.17 18 PROBAST 
provides signalling questions to facilitate both the appli-
cability and risk of bias assessment of prediction model 
studies across four domains: participants, predictors, 
outcome and analysis. This assessment can only be 
correctly implemented if prediction model studies are 
properly reported. Although TRIPOD and PROBAST 
both covered all types of prediction modelling studies, 
including those using ML techniques, their focus was on 
regression- based modelling. The challenges and necessity 
for reporting and quality assessment guidelines in the AI/
ML field have been addressed by several authors and this 
has led to initiatives, such as Consolidated Standards of 
Reporting Trials- AI (for randomised controlled trials), 
and Standard Protocol Items: Recommendations for 
Interventional Trials- AI (for clinical trial protocols). Simi-
larly, for prediction model studies using ML, TRIPOD- ML 
and PROBAST- ML have been announced.19–21
To improve the quality, transparency and usability of 
ML- based prediction models in medicine, it is important 
to explore the current use and reporting of ML tech-
niques in prediction model studies, to evaluate the meth-
odological conduct and risk of bias using PROBAST, 
and assess the adherence to TRIPOD by performing a 
comprehensive systematic review.3 15–18 22
Study aim
The primary aim of this systematic review is to evaluate 
the reporting and the methodological conduct of studies 
reporting on prediction models developed with super-
vised ML techniques, across all medical fields. Specific 
objectives are to:
1. Evaluate the reporting quality of prediction models de-
veloped using ML techniques based on TRIPOD.
2. Assess the methodological quality and the risks of bias 
in prediction model development or validation studies 
using ML techniques based on PROBAST.
3. Identify key and emerging concepts for the develop-
ment of tailored adaptations or extensions of both 
TRIPOD and PROBAST.
METHODS AND ANALYSIS
Our systematic review protocol was registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO) on 19 December 2019 (CRD42019161764). 
This protocol was prepared using the Preferred Reporting 
Items for Systematic Reviews and Meta- Analysis Protocols 
(PRISMA- P) 2015 statement.23
Eligibility criteria
Articles will be eligible for this review when describing 
primary studies on the development and/or validation 
of a multivariable diagnostic or prognostic prediction 
model with at least two predictors, using any supervised 
ML methodology within all medical fields, and published 
between January 2018 and December 2019. This last 
inclusion criterion is to obtain the most contemporary 
sample of articles that would reflect the current practices 
of applied methods in the ML prediction model field. We 
will include studies with any study design and data source, 
all patient- related health outcomes, all outcome formats 
and restricted to humans only. Further details about 
inclusion criteria are given in table 1.
Articles will be excluded from this review when reporting 
models that make predictions for enhancing the reading 
of images or signals (rather than for prediction of health 
outcomes in individuals), or use only genetic or molec-
ular markers as candidate predictors. Furthermore, prog-
nostic factor studies, secondary research, conference 
abstracts and studies for which no full text is available will 
also be excluded. The search will be restricted to articles 
available in English only. Further details about exclusion 
criteria are given in table 2.
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Information sources
A literature search will be systematically applied in one 
major public- available electronic medical literature data-
bases from 01 January 2018 to 31 December 2019.
Search strategy
The search strategy was built using keywords including 
ML- related terms (ie, ‘supervised learning’, ‘support 
vector machine’, ‘neural network’), prediction- related 
terms24 (ie, ‘risk’, ‘prognosis’) and several performance 
measures for prediction modelling (ie, ‘AUC’, ‘O:E ratio’). 
For search refinement, we selected 30 articles aligned 
with our inclusion/exclusion criteria to create a ‘golden 
bullet’ set. This set was analysed using SWIFT- Reviewer 
to obtain the most frequent words in the included arti-
cles by topic modelling.25 In MedlinerRanker, the anal-
ysis of the included and excluded golden bullets articles 
allowed us to obtain the most discriminative words to 
be considered in the search strategy.26 The final search 
strategy is presented in online supplemental file 1.
Study records
Data management
Study record information including title and abstract 
from the searched online database will be imported 
into EndNote Citation Manager and Rayyan systematic 
review software.27 These platforms will track and back up 
all activities when authors conduct the literature review 
process. Once eligible studies are identified, full- text arti-
cles will be downloaded for full- text screening and data 
extraction. Data items (below) will be extracted from 
the final included studies for review using Research Data 
Capture (REDCap) software.28
Table 1 Definition of inclusion criteria
Inclusion criteria Definition
Any study design Articles that report the development and/or validation of a prediction model based on experimental 
studies or observational studies. This includes randomised controlled trials, prospective and 
retrospective cohort, case–control studies and case–cohort studies.
Using at least 2 predictors for risk 
prediction
Articles that report the development and/or validation of a prediction model using at least two predictors. 
Articles that use imaging or speech parameters as structured data plus other predictors such as clinical, 
demographics, histological and genetic risk scores features will be included.
Any data sources Articles that report the development and/or validation of a prediction model using any structured data 
source, for example, electronic medical records, administrative claims data and individual patient data 
meta- analysis data.
Any supervised ML technique Articles that report the use of any ML technique for development and/or validation of a prediction model. 
We will consider as a ML technique, a statistical technique based on advanced computational capacity 
and lower human intervention. More specifically, we will focus on supervised ML techniques.
Patient health- related outcomes Articles that report the development and/or validation of a prediction model whose main outcome is on 
an individual patient level. We will include articles assessing diagnosis, prognosis and health services 
performance, such as length of stay or triage assessment.
All outcome measures format Articles that report the development and/or validation of a prediction model whose main outcome has 
one of the following formats: continuous, binary, ordinal, multinomial and time- to- event.
ML, machine learning.
Table 2 Definition of exclusion criteria
Exclusion criteria Definition
Images or signal studies Articles that report the development and/or validation of a prediction model for enhancing the reading of images, 
pathological samples or signals. The purpose of these articles is to improve the accuracy of an instrument rather than 
providing a clinical outcome.
Only genetic and/or 
molecular predictors
Articles that report the development and/or validation of a prediction model using only genetic and/or molecular candidate 
predictors. These articles are often based on high- dimensional data and unsupervised ML techniques.
Prognostic factors 
studies
Articles that report the identification of prognostic factors associated with a clinical outcome in an individual.
Secondary research Articles that report narrative reviews, systematic reviews about prediction model studies in a specific medical field. 
Guidelines, expert’s opinions and letters to the editor will also be excluded.
Conference abstract Articles that report the development and/or validation of a prediction model presented in a conference. Such articles, by 
definition, do not report all the information required for assessment.
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Selection process
Two researchers, from a group of seven (CLAN, TT, 
SWJN, PD, JM, RB, JAAGD), will independently screen 
the titles and abstracts to identify eligible studies 
according to the eligibility criteria. Two independent 
researchers, from the combination of the previous seven 
reviewers, will review the full text for potentially eligible 
articles; one researcher (CLAN) will screen all articles 
and six researchers (TT, SWJN, PD, JM, RB, JAAGD) will 
collectively screen a portion of the same articles for agree-
ment. Disagreements between reviewers will be solved 
by consensus or consultation with a third investigator, if 
necessary (JAAGD). The study flow will be presented in a 
PRISMA flowchart.29
Data collection process
We will perform a double data extraction for all included 
articles. Two reviewers will independently extract data 
from each article using a standardised data extraction 
form. One researcher (CLAN) will extract data from all 
articles and six other researchers (TT, SWJN, PD, JM, 
RB, JAAGD) will collectively extract data from the same 
articles. The data extraction form will be piloted on five 
papers and amended, if necessary. Disagreements in data 
extraction will be discussed between the two reviewers, 
and adjudicated by a third reviewer (KGMM, GSC, RDR 
or LH), if necessary. The authors of the articles will be 
contacted for further information and clarification, if 
needed. Data and records will be maintained by the lead 
investigator (CLAN) and stored on a shared secure plat-
form for access by all investigators (REDCap).
Data items
Data to be extracted will be informed by TRIPOD using the 
TRIPOD adherence guidance, PROBAST and the CHeck-
list for critical Appraisal and data extraction for system-
atic Reviews of prediction Modelling Studies.15–18 22 30 
Additional items specifically relating to ML techniques 
for prediction model purposes, will also be extracted.
Extracted data will include study design for the devel-
opment and validation of the model, outcomes to be 
predicted, setting, the intended use of the prediction 
model, study population, data source, patient charac-
teristics, total study sample size, number of individuals 
with the outcome, number of predictors (candidate and 
final), internal validation type, predictive performance 
measures (discrimination and calibration), number of 
models developed and the details of the ML technique 
used to develop each model (eg, technique, prepro-
cessing, data cleaning, optimisation algorithm, predic-
tors selection, penalisation techniques, hyperparameters, 
code, data availability and so on). This form will contain 
instructions for the reviewers on how to assess the models 
presented in the articles. For example, the number of 
models developed will be based on how many ML tech-
niques were used, including if several hyperparameters 
are tuned. We will set a limit to the number of models for 
data extraction to 10. The number of predictors will be 
counted based on what is reported in the article and/or 
supplemental file. If not stated, the number of predictors 
will be reported as unclear. The final data extraction form 
is presented in online supplemental file 2.
Outcomes
The primary outcomes of this systematic review are the 
adherence to the TRIPOD reporting guideline and the 
risk of bias assessed using PROBAST.17 18 22
Assessment of risk of bias
The risk of bias of individual studies is one of our outcomes 
of interest and will be assessed using PROBAST.17 18
Data synthesis
We will conduct a narrative synthesis of the extracted 
data. Data will be summarised using descriptive statistics 
and visual plots. Numbers and percentages will be used 
to describe categorical data about the reporting, meth-
odological conduct and risks of bias of the studies. The 
distribution of continuous data, such as sample size and 
the number of predictors, will be assessed and described 
using mean and SD for normally distributed data and 
using median and 25th and 75th percentiles for non- 
normally distributed data. The risk of bias assessment 
will be summarised and graphically presented for each 
PROBAST domain and as an overall risk of bias judge-
ment. Results will be stratified by study type (develop-
ment with internal validation and/or external validation), 
medical field and prevalent ML techniques.
Meta-bias(es)
Meta- bias will not be investigated in this study.
Confidence in cumulative evidence
The strength of the body of evidence will not be assessed 
in this study.
Amendments
Protocol amendments will be listed and made available 
on the PROSPERO registration. Date, description and 
rationale will be given for each amendment.
ETHICS AND DISSEMINATION
Ethical approval is not required for this study because 
only available published data will be analysed. The find-
ings of this systematic review will be published in an open- 
access journal to ensure access for all stakeholders and 
disseminated in various scientific conferences.
Patient and public involvement
Not applicable.
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DISCUSSION
The use of ML has been increasingly recognised as a 
powerful tool to improve healthcare by enabling related 
professionals to make decisions based on the increas-
ingly available and diverse sources of (bio)medical data. 
Particularly, ML- based prediction algorithms that are 
considered the key to unlock the increasingly available 
data sources, are intended to better inform real- time clin-
ical decisions, support early warning systems and provide 
superhuman imaging diagnostics.31 However, published 
research about this topic rarely provides adequate infor-
mation about the final predictive model, and its estimates 
and performance. Even more scarce is research where the 
prediction model is accessible for patients and healthcare 
professionals alike. Hence, ML- based prediction model 
studies are often seen as uninterpretable. This aspect of 
ML techniques is problematic especially in medical diag-
nosis and prognosis, hampering the judgement of quality, 
clinical acceptance and implementation.
At present, there is a limited number of systematic 
reviews regarding the reporting and methodological 
quality of ML- based prediction model studies and their 
risks of bias.32–34 In this systematic review, we will review 
across all medical fields, the current use of ML tech-
niques in prediction model development, validation 
and updating studies, the methodological conduct and 
risks of bias using PROBAST, and the adherence to the 
reporting guideline using TRIPOD. Particularly, we will 
assess the extent to which risks of bias and reporting of 
ML- based prediction model studies match the current 
recommendations from TRIPOD and PROBAST,22 and 
the implications of these results to update or extend them 
to TRIPOD- ML and PROBAST- ML.
So far, our findings should be considered within limita-
tions. ML is a recently developed concept and without 
a clear scope yet. Therefore, a sensitive search strategy 
is hard to build, which may result in a large number of 
abstracts to screen at initial stages. Additionally, we are 
only able to include articles in English, which will under- 
represent research available in other languages.
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